Journal article icon

Journal article

Transcriptional reprogramming via signaling domains of CD2, CD28, and 4-1BB

Abstract:

Costimulatory signals provided to T cells during antigen encounter have a decisive role in the outcome of immune responses. Here, we used chimeric receptors harboring the extracellular domain of mouse inducible T cell costimulator (mICOS) to study transcriptional activation mediated by cytoplasmic sequences of the major T cell costimulatory receptors CD28, 4-1BB, and CD2. The chimeric receptors were introduced in a T cell reporter platform that allows to simultaneously evaluate nuclear factor κB (NF-κB), NFAT, and AP-1 activation. Engagement of the chimeric receptors induced distinct transcriptional profiles. CD28 signaling activated all three transcription factors, whereas 4-1BB strongly promoted NF-κB and AP-1 but downregulated NFAT activity. CD2 signals resulted in the strongest upregulation of NFAT. Transcriptome analysis revealed pronounced and distinct gene expression signatures upon CD2 and 4-1BB signaling. Using the intracellular sequence of CD28, we exemplify that distinct signaling motifs endow chimeric receptors with different costimulatory capacities.

Publication status:
Published
Peer review status:
Peer reviewed

Actions

Access Document

Publisher copy:
10.1016/j.isci.2024.109267

Authors

More by this author
Institution:
University of Oxford
Division:
MSD
Department:
Radcliffe Department of Medicine
Role:
Author
ORCID:
0000-0003-0598-2181


More from this funder
Funder identifier:
https://ror.org/013tf3c58
Grant:
P32411


Publisher:
Cell Press
Journal:
iScience More from this journal
Volume:
27
Issue:
3
Article number:
109267
Publication date:
2024-02-19
Acceptance date:
2024-02-14
DOI:
EISSN:
2589-0042
Pmid:
38455974


Language:
English
Keywords:
Pubs id:
1725255
Local pid:
pubs:1725255
Deposit date:
2025-05-07
ARK identifier:

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP